Detalles de la búsqueda
1.
Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.
Blood
; 140(8): 851-860, 2022 08 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-35679476
2.
Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis.
Haemophilia
; 29(4): 1087-1094, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37347645
3.
Incorporating Prior Beliefs Into Meta-Analyses of Health-State Utility Values Using the Bayesian Power Prior.
Value Health
; 26(9): 1389-1397, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37187235
4.
Health Utility Analysis of Tepotinib in Patients With Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping.
Value Health
; 26(8): 1155-1163, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36805576
5.
Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: An indirect comparison using clinical trial data.
Clin Nephrol
; 97(5): 261-272, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-34931610
6.
Real-world evidence use in assessments of cancer drugs by NICE.
Int J Technol Assess Health Care
; : 1-7, 2020 Jul 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32646531
7.
Migraine day frequency in migraine prevention: longitudinal modelling approaches.
BMC Med Res Methodol
; 19(1): 20, 2019 01 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-30674285
8.
Longitudinal assessment of utilities in patients with migraine: an analysis of erenumab randomized controlled trials.
Health Qual Life Outcomes
; 17(1): 171, 2019 Nov 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31718662
9.
Frequentist and Bayesian meta-regression of health state utilities for multiple myeloma incorporating systematic review and analysis of individual patient data.
Health Econ
; 28(5): 653-665, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30790379
10.
Estimating outcomes and cost effectiveness using a single-arm clinical trial: ofatumumab for double-refractory chronic lymphocytic leukemia.
Cost Eff Resour Alloc
; 15: 8, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28559746
11.
The Cost of Costing Treatments Incorrectly: Errors in the Application of Drug Prices in Economic Evaluation Due to Failing to Account for the Distribution of Patient Weight.
Value Health
; 19(8): 1055-1058, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27987632
12.
Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death.
Health Qual Life Outcomes
; 12: 140, 2014 Sep 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-25214238
13.
Modelling Health State Utilities as a Transformation of Time to Death in Patients with Non-Small Cell Lung Cancer.
Pharmacoeconomics
; 42(1): 109-116, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37707719
14.
Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK.
Target Oncol
; 19(2): 191-201, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38492157
15.
Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A.
Adv Ther
; 41(6): 2267-2281, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38616241
16.
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.
Expert Rev Anticancer Ther
; 23(2): 199-206, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36723678
17.
Carers' Health-Related Quality of Life in Global Health Technology Assessment: Guidance, Case Studies and Recommendations.
Pharmacoeconomics
; 40(9): 837-850, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35821351
18.
Approaches to Selecting "Time Zero" in External Control Arms with Multiple Potential Entry Points: A Simulation Study of 8 Approaches.
Med Decis Making
; 42(7): 893-905, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35514320
19.
What is the Impact of the Analysis Method Used for Health State Utility Values on QALYs in Oncology? A Simulation Study Comparing Progression-Based and Time-to-Death Approaches.
Appl Health Econ Health Policy
; 19(3): 389-401, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33314001
20.
Survival outcomes and treatment costs for patients with double-refractory chronic lymphocytic leukaemia (DR-CLL).
Br J Haematol
; 169(3): 449-52, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25410960